Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Koshinski Asset Management Inc.

Koshinski Asset Management Inc. decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 66.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 500 shares of the pharmaceutical company’s stock after selling 1,004 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Vertex Pharmaceuticals were worth $203,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Sherbrooke Park Advisers LLC grew its position in Vertex Pharmaceuticals by 65.3% in the 3rd quarter. Sherbrooke Park Advisers LLC now owns 2,645 shares of the pharmaceutical company’s stock worth $920,000 after purchasing an additional 1,045 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its position in Vertex Pharmaceuticals by 6.5% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 432,937 shares of the pharmaceutical company’s stock worth $150,550,000 after purchasing an additional 26,523 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Vertex Pharmaceuticals by 1.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 427,001 shares of the pharmaceutical company’s stock worth $148,485,000 after purchasing an additional 5,514 shares during the last quarter. Machina Capital S.A.S. bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth about $816,000. Finally, Morgan Stanley grew its position in Vertex Pharmaceuticals by 3.2% in the 3rd quarter. Morgan Stanley now owns 2,870,101 shares of the pharmaceutical company’s stock worth $998,050,000 after purchasing an additional 89,217 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares in the company, valued at approximately $31,250,727.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Vertex Pharmaceuticals news, COO Stuart A. Arbuckle sold 4,295 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the sale, the chief operating officer now owns 75,718 shares in the company, valued at approximately $31,819,732.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Canaccord Genuity Group reiterated a “sell” rating and issued a $371.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, April 12th. Robert W. Baird cut shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price objective for the company. in a report on Wednesday, January 31st. Maxim Group cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. StockNews.com upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, April 12th. Finally, Evercore ISI upgraded shares of Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price objective for the company in a report on Thursday, April 11th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $424.62.

Vertex Pharmaceuticals Stock Down 0.8 %

Shares of NASDAQ:VRTX opened at $394.17 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. The company has a market cap of $101.88 billion, a PE ratio of 28.38, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35. Vertex Pharmaceuticals Incorporated has a 52 week low of $316.43 and a 52 week high of $448.40. The firm has a 50 day simple moving average of $415.28 and a 200 day simple moving average of $396.78.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating the consensus estimate of $3.85 by $0.35. The business had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same quarter in the prior year, the firm earned $3.33 EPS. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.